WO2022104692 ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Publication Number WO/2022/104692

Publication Date 27.05.2022

International Application No. PCT/CN2020/130409

International Filing Date 20.11.2020

IPC

CPC

View more classifications

View less classifications

Applicants

BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. [CN]/[CN]

Inventors

XIA, Bing
ZHOU, Yuhong
WEI, Ziping
YANG, Jianfeng

Agents

SHANGHAI BESHINING LAW OFFICE

Priority Data

Publication Language English (en)

Filing Language English (EN)

Designated States

View all

Title

(EN) ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

(FR) ANTICORPS MODIFIÉ, CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION

Abstract

(EN) An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.

(FR) Un anticorps IgG isolé comprend deux chaînes lourdes identiques ayant chacune une région charnière avec une séquence d'acides aminés contenant une cystéine supplémentaire en amont des deux cystéines dans la séquence CPPCP d'une région charnière d'IgG native, et un domaine CH1 contenant une cystéine à la position 142 selon le système de numérotation IMGT. L'invention concerne également des ADC basés sur l'anticorps ayant cette architecture.

Latest bibliographic data on file with the International Bureau

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39	Medicinal preparations containing antigens or antibodies
395	Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18	against material from animals or humans
28	against receptors, cell surface antigens or cell surface determinants

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35	Antineoplastic agents

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39	Medicinal preparations containing antigens or antibodies
395	Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
K	PEPTIDES
16	Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18	against material from animals or humans
28	against receptors, cell surface antigens or cell surface determinants

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. WO2022104692 - ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF

C	CHEMISTRY; METALLURGY
12	BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N	MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15	Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09	Recombinant DNA-technology
63	Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79	Vectors or expression systems specially adapted for eukaryotic hosts
85	for animal cells

G	PHYSICS
01	MEASURING; TESTING
N	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33	Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48	Biological material, e.g. blood, urine
50	Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53	Immunoassay; Biospecific binding assay; Materials therefor
574	for cancer

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
33	Heterocyclic compounds
395	having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535	having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375	1,4-Oxazines, e.g. morpholine
5377	not condensed and containing further heterocyclic rings, e.g. timolol

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
33	Heterocyclic compounds
395	having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55	having seven-membered rings, e.g. azelastine, pentylenetetrazole
551	having two nitrogen atoms, e.g. dilazep
5513	1,4-Benzodiazepines, e.g. diazepam ; or clozapine
5517	condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
68	the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
33	Heterocyclic compounds
395	having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535	having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375	1,4-Oxazines, e.g. morpholine
5377	not condensed and containing further heterocyclic rings, e.g. timolol